A carregar cotações...

Previsão

Não temos dados de analistas para esta empresa.

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

Notícias Ir para o feed de notícias

Oncopeptides: revenue in second quarter rises 62%, shares jump

Oncopeptides reported net sales of SEK 31.1m in Q2 2026, up 62% year‑on‑year, and SEK 56.5m in the first half (+74%). Gross margin in H1 was 98%, the EBIT loss narrowed to SEK 86.2m, and operating costs fell slightly. The company reported SEK 158m in cash after a March rights issue and reiterated its target to reach positive cash flow in 2027. The share rose about 10% in early trading but remains well below the 52‑week high. » Mais em de.investing.com
Oncopeptides: Q3 revenue rises 174% – profitability targeted by end of 2026

Oncopeptides reports Q3 2025 revenue of SEK 20.2m, up 174% year‑on‑year, and a gross margin of 99%. EBIT improved to -SEK 47.1m but remained negative, while operating expenses were slightly reduced. After an oversubscribed rights issue, liquidity stands at SEK 147.9m; the company aims for positive cash flow by the end of 2026. Oncopeptides is advancing commercialization in Europe (Germany, Spain, Italy) and is negotiating partnerships in Japan, but uncertainty over growth and timing failed to reassure investors, sending the stock down nearly 14%. » Mais em de.investing.com
Oncopeptides achieves 174% revenue increase, stock falls sharply in pre-market

Oncopeptides reported Q3 2025 net revenue growth of 174% to SEK 20.2m and a gross profit of SEK 19.9m with a gross margin of 99%. Operating expenses fell 3% and EBIT improved from -SEK 61.3m to -SEK 47.1m; after a capital raise liquidity stands at SEK 147.9m. Despite the progress, the stock fell 12.44% in pre-market trading as investors voiced concerns about operational challenges, market expansion and the timeline to profitability by end-2026. Management plans to expand its market presence in Europe and will present further details at the capital markets day on 13 November. » Mais em de.investing.com
Oncopeptides reports strong Q2 growth, plans SEK 150m rights issue

Oncopeptides posted net sales of SEK 19.2m in Q2 2025 (+45% q/q, +135% y/y) and has recorded three quarters with >30% growth, while the stock fell sharply in pre-market trading. The company plans a rights issue of SEK 150m, holds SEK 70m in cash and is targeting positive cash flow by 2026. Pepaxti was included in EMN guidelines and approved in markets such as Germany, Spain and Italy; partnership negotiations for Japan are ongoing. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Oncopeptides registou receitas de € 2,51 mi e um ganho líquido de -€ 3,88 mi

(EUR)	setembro de 2026	YoY
Receitas	2,51 mi	37,22%
Ganho bruto	2,47 mi	36,92%
Ganho líquido	-3,88 mi	29,60%
EBITDA	-3,17 mi	24,62%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 68,75 mi
Número de ações	431,36 mi
Máximo/mínimo de 52 semanas	€ 0,52 - € 0,11
Dividendos	Não
Beta	-1,41
PER (PE Ratio)	-2,81
PEG (PEG Ratio)	-0,04
P/VC (PB Ratio)	-39,32
P/V (PS Ratio)	7,38

Perfil da empresa

A Oncopeptides AB (publ), uma empresa de biotecnologia, desenvolve medicamentos farmacêuticos para o tratamento do cancro nos Estados Unidos, na Europa e a nível internacional. O seu principal candidato a produto é o melflufen, um fármaco conjugado peptídico anticancerígeno para o tratamento do mieloma múltiplo recidivante e refratário em doentes adultos. A Oncopeptides AB (publ) foi constituída em 2000 e tem sede em Estocolmo, na Suécia.